Clinic
Boston Medical Center Corporation
Boston Medical Center Corporation was paid $9.88M by Medicaid between Jan 2018 and Dec 2024, across 243 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 30% of everything it billed.
33Billing provider infoBOSTON MEDICAL CENTER CORPORATION
ROSLINDALE, MA 02131
ROSLINDALE, MA 02131
33aNPI1386718823assigned 11/17/2006
33bProvider typeCommunity Health Clinic/Center
28Total paid$9.88M
24GClaims268,793
24DCodes billed243
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Community Health Clinic/Center providers in Massachusetts
Rank by total paid#15 of 36
Median peer was paid$3.62M
This provider vs. median2.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 28,859 | $1.04M | |
| 2019 | 25,008 | $977K | |
| 2020 | 41,121 | $1.97M | |
| 2021 | 40,670 | $1.76M | |
| 2022 | 43,616 | $2.21M | |
| 2023 | 46,325 | $1.18M | |
| 2024incomplete | 43,194 | $750K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 30% | 48,024 | 43,626 | $2.97M |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 13% | 8,160 | 7,582 | $1.25M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 12% | 16,705 | 15,532 | $1.19M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 2.4% | 2,598 | 2,593 | $233K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 2.0% | 2,228 | 2,221 | $201K |
| D9450 | 1.8% | 16,814 | 9,973 | $176K | |
| D1110 | Prophylaxis - adult | 1.7% | 5,384 | 4,040 | $167K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.6% | 1,491 | 1,393 | $157K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.5% | 1,456 | 1,344 | $146K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.4% | 6,897 | 5,676 | $143K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 1.4% | 1,649 | 1,642 | $136K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 1.4% | 1,759 | 1,756 | $135K |
231 more codes
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 1.3% | 12,207 | $133K |
| 99215 | Doctor's office visit, returning patient (complex) | 1.2% | 1,060 | $123K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.2% | 4,334 | $115K |
| 90834 | Psychotherapy session, about 45 minutes | 1.1% | 1,317 | $113K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | 1.1% | 1,384 | $111K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.1% | 4,254 | $109K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 969 | $88K |
| 87481 | <1% | 1,419 | $84K | |
| 99283 | Emergency room visit (moderate) | <1% | 473 | $81K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,139 | $75K |
| D0120 | Dental checkup, returning patient | <1% | 4,482 | $70K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 4,024 | $65K |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 1,178 | $61K |
| 99285 | Emergency room visit (most serious) | <1% | 301 | $56K |
| D0274 | Bitewings - four radiographic images | <1% | 2,261 | $55K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 4,475 | $55K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,935 | $50K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,702 | $49K |
| 99188 | <1% | 1,808 | $47K | |
| D1120 | Dental cleaning, child | <1% | 1,028 | $44K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 122 | $44K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 329 | $44K |
| D0210 | Intraoral - complete series of radiographic images | <1% | 1,145 | $44K |
| 87511 | <1% | 1,421 | $43K | |
| D1206 | Topical application of fluoride varnish | <1% | 1,613 | $41K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 283 | $39K |
| 99284 | Emergency room visit (serious) | <1% | 244 | $38K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,473 | $37K |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 1,397 | $36K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 802 | $34K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 285 | $34K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,497 | $34K |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 713 | $33K |
| 86780 | <1% | 3,208 | $31K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,232 | $30K |
| 86480 | <1% | 604 | $28K | |
| 80050 | General health panel | <1% | 2,084 | $26K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,160 | $25K |
| 86803 | <1% | 2,583 | $25K | |
| 90715 | <1% | 1,258 | $24K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 171 | $23K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,152 | $23K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 5,291 | $22K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 4,084 | $22K |
| D9110 | <1% | 860 | $22K | |
| 90651 | <1% | 1,020 | $20K | |
| 80061 | Lipid panel | <1% | 6,164 | $19K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 156 | $19K |
| 90670 | <1% | 703 | $18K | |
| 0012A | <1% | 680 | $18K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 110 | $17K |
| 91322 | <1% | 229 | $16K | |
| 90686 | <1% | 2,373 | $14K | |
| 0011A | <1% | 673 | $14K | |
| 88142 | <1% | 784 | $14K | |
| 90756 | <1% | 793 | $13K | |
| 90480 | <1% | 305 | $12K | |
| 90746 | <1% | 354 | $12K | |
| 84703 | <1% | 1,816 | $12K | |
| 92552 | <1% | 436 | $11K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 341 | $11K |
| 90688 | <1% | 626 | $11K | |
| 99173 | <1% | 1,175 | $10K | |
| 90677 | <1% | 411 | $10K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 262 | $10K |
| 0001A | <1% | 215 | $10K | |
| 0064A | <1% | 354 | $9K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,246 | $9K |
| 0002A | <1% | 205 | $9K | |
| D0220 | Intraoral - periapical first radiographic image | <1% | 965 | $9K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,453 | $9K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 205 | $8K |
| 0004A | <1% | 191 | $8K | |
| 92551 | <1% | 798 | $8K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 17 | $8K |
| 87486 | <1% | 284 | $7K | |
| 87581 | <1% | 284 | $7K | |
| 82728 | <1% | 630 | $7K | |
| 97161 | <1% | 27 | $7K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 52 | $6K |
| 90661 | <1% | 650 | $6K | |
| 83550 | <1% | 856 | $6K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 428 | $6K |
| 80053 | Comprehensive metabolic panel | <1% | 1,595 | $6K |
| 86706 | <1% | 691 | $5K | |
| 0071A | <1% | 135 | $5K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,852 | $5K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 34 | $5K |
| 0072A | <1% | 112 | $5K | |
| 0134A | <1% | 136 | $5K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 103 | $5K |
| 86765 | <1% | 217 | $5K | |
| 90716 | <1% | 164 | $5K | |
| 82274 | <1% | 391 | $4K | |
| 0124A | <1% | 107 | $4K | |
| 90734 | <1% | 256 | $4K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 59 | $4K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 25 | $3K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 50 | $3K |
| 90658 | <1% | 241 | $3K | |
| 87340 | <1% | 428 | $3K | |
| 86762 | <1% | 270 | $3K | |
| 90707 | <1% | 181 | $3K | |
| 86787 | <1% | 263 | $3K | |
| 85018 | <1% | 1,273 | $3K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 51 | $3K |
| G0378 | Hospital observation service, per hour | <1% | 24 | $3K |
| 86735 | <1% | 216 | $2K | |
| 81003 | <1% | 1,359 | $2K | |
| 81001 | <1% | 1,111 | $2K | |
| 87081 | <1% | 386 | $2K | |
| 82607 | <1% | 225 | $2K | |
| 82043 | <1% | 867 | $2K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 39 | $2K |
| 82805 | <1% | 47 | $2K | |
| 70355 | <1% | 31 | $2K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 143 | $2K |
| 99442 | <1% | 41 | $2K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 14 | $2K |
| 99385 | <1% | 45 | $2K | |
| 90837 | Psychotherapy session, about an hour | <1% | 14 | $2K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 13 | $2K |
| D0180 | <1% | 108 | $2K | |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 58 | $2K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 492 | $2K |
| 85027 | <1% | 309 | $2K | |
| 99382 | <1% | 12 | $1K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 13 | $1K |
| 82746 | <1% | 147 | $1K | |
| 90674 | <1% | 52 | $1K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 13 | $1K |
| D2150 | Silver amalgam - two surfaces, primary or permanent | <1% | 23 | $1K |
| 11719 | <1% | 154 | $1K | |
| D0140 | Limited oral evaluation - problem focused | <1% | 33 | $972.00 |
| J3490 | Unclassified drugs | <1% | 26 | $958.44 |
| 84439 | <1% | 134 | $954.10 | |
| 90662 | <1% | 153 | $884.22 | |
| 84702 | <1% | 70 | $851.88 | |
| 91301 | <1% | 576 | $774.90 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 51 | $744.60 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 16 | $716.28 |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 162 | $713.16 |
| 87536 | <1% | 18 | $698.58 | |
| 86850 | <1% | 132 | $670.98 | |
| 91300 | <1% | 315 | $664.20 | |
| 90633 | <1% | 329 | $635.40 | |
| 90694 | <1% | 67 | $625.84 | |
| 84484 | <1% | 84 | $555.86 | |
| 87522 | Neg quan hep c or qual rna | <1% | 15 | $546.98 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 102 | $498.96 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 73 | $498.96 |
| J2704 | Injection, propofol, 10 mg | <1% | 58 | $498.96 |
| 83605 | <1% | 63 | $468.00 | |
| G0008 | Administration of influenza virus vaccine | <1% | 503 | $460.15 |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 75 | $454.35 |
| 86708 | <1% | 42 | $448.13 | |
| 86141 | <1% | 53 | $436.97 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 16 | $397.45 |
| 83690 | <1% | 81 | $383.69 | |
| 90732 | <1% | 25 | $378.97 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 49 | $374.22 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 37 | $374.22 |
| 87430 | <1% | 32 | $372.60 | |
| ATP03 | <1% | 232 | $359.27 | |
| 90619 | <1% | 206 | $329.30 | |
| 87641 | <1% | 16 | $320.10 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 44 | $311.85 |
| 83970 | <1% | 17 | $301.20 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 13 | $288.09 |
| 83735 | <1% | 103 | $287.17 | |
| 86753 | <1% | 25 | $284.18 | |
| 86900 | <1% | 132 | $275.40 | |
| 86901 | <1% | 132 | $270.37 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 102 | $250.52 |
| 90656 | <1% | 120 | $244.71 | |
| 87186 | <1% | 33 | $228.52 | |
| 91307 | <1% | 270 | $221.40 | |
| 85610 | <1% | 110 | $214.80 | |
| 83540 | <1% | 56 | $213.67 | |
| 73610 | <1% | 17 | $181.60 | |
| 83655 | <1% | 1,294 | $164.42 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 13 | $154.24 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 13 | $141.65 |
| 85652 | <1% | 70 | $132.84 | |
| 85730 | <1% | 29 | $126.04 | |
| 86580 | <1% | 13 | $119.80 | |
| 87077 | <1% | 15 | $95.81 | |
| 82570 | <1% | 37 | $94.40 | |
| 73630 | <1% | 16 | $90.80 | |
| 90653 | <1% | 31 | $82.64 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 18 | $79.28 |
| 80076 | <1% | 14 | $66.03 | |
| 82330 | <1% | 47 | $64.64 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 17 | $62.34 |
| 82465 | <1% | 13 | $52.06 | |
| 82248 | <1% | 65 | $46.14 | |
| 84156 | <1% | 20 | $36.85 | |
| Q2038 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | <1% | 26 | $34.91 |
| 82550 | <1% | 15 | $32.61 | |
| 84450 | <1% | 12 | $29.58 | |
| 82947 | <1% | 12 | $29.58 | |
| 84460 | <1% | 12 | $29.56 | |
| 82962 | <1% | 251 | $21.78 | |
| 82565 | <1% | 13 | $16.39 | |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 13 | $10.50 |
| 91313 | <1% | 94 | $0.01 | |
| 91306 | <1% | 256 | $0.01 | |
| 90648 | 0% | 320 | $0.00 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 50 | $0.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 15 | $0.00 |
| 84100 | 0% | 19 | $0.00 | |
| 91312 | 0% | 83 | $0.00 | |
| 99218 | 0% | 74 | $0.00 | |
| 91321 | 0% | 45 | $0.00 | |
| 90681 | 0% | 12 | $0.00 | |
| 90685 | 0% | 16 | $0.00 | |
| 90710 | 0% | 15 | $0.00 | |
| 90700 | 0% | 17 | $0.00 | |
| 90697 | 0% | 247 | $0.00 | |
| 71045 | Radiologic examination, chest; single view | 0% | 14 | $0.00 |
| 80320 | 0% | 47 | $0.00 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 36 | $0.00 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 0% | 131 | $0.00 |
| 90723 | 0% | 154 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 77 | $0.00 |
| 96375 | Therapeutic injection; each additional sequential IV push | 0% | 88 | $0.00 |
| 96376 | 0% | 21 | $0.00 | |
| 36416 | 0% | 33 | $0.00 | |
| 80329 | 0% | 13 | $0.00 | |
| 90474 | 0% | 17 | $0.00 | |
| G0009 | Administration of pneumococcal vaccine | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNEWSOM, TERESA (SVP, CFO)
Parent organizationBOSTON MEDICAL CENTER CORPORATION
| Provider | Location | Paid |
|---|---|---|
| Greenville Health System | Simpsonville, SC | $29K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.